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MaOBJECTIVES The aim of this study was to determine the impact of the degree of residual aortic regurgitation (AR)
and acuteness of presentation of AR after transcatheter aortic valve replacement (TAVR) on outcomes.
BACKGROUND The degree of residual AR after TAVR leading to excess mortality remains controversial, and little
evidence exists on the impact of the acuteness of presentation of AR.
METHODS A total of 1,735 patients undergoing TAVR with balloon-expandable or self-expanding valves were included.
The presence and degree of AR were evaluated by transthoracic echocardiography; acute AR was deﬁned as an increase
in AR severity of $1 degree compared with pre-procedural echocardiography.
RESULTS Residual AR was classiﬁed as mild in 761 patients (43.9%) and moderate to severe in 247 patients (14.2%).
The presence of moderate to severe AR was an independent predictor of mortality at a mean follow-up of 21  17 months
compared with none to trace (adjusted hazard ratio [HR]: 1.81, 95% conﬁdence interval [CI]: 1.32 to 2.48; p < 0.001) and
mild AR (adjusted HR: 1.68, 95% CI: 1.27 to 2.24; p < 0.001) groups. There was no increased risk in patients with mild AR
compared with those with none to trace AR (p ¼ 0.393). In patients with moderate to severe AR, acute AR was observed
in 161 patients (65%) and chronic AR in 86 patients (35%). Acute moderate to severe AR was independently associated
with increased risk of mortality compared with none/trace/mild AR (adjusted HR: 2.37, 95% CI: 1.53 to 3.66; p < 0.001)
and chronic moderate to severe AR (adjusted HR: 2.24, 95% CI: 1.17 to 4.30; p ¼ 0.015). No differences in survival rate
were observed between patients with chronic moderate to severe and none/trace/mild AR (p > 0.50).
CONCLUSIONS AR occurred very frequently after TAVR, but an increased risk of mortality at w2-year follow-up
was observed only in patients with acute moderate to severe AR. (J Am Coll Cardiol Intv 2014;7:1022–32)
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1023TABLE 1 Baseline Clinical Characteristics and Echocardiographic and Procedural
Findings According to the Severity of AR After TAVR
All
(n ¼ 1,735)
None to
Trace AR
(n ¼ 727)
Mild AR
(n ¼ 761)
Moderate to
Severe AR
(n ¼ 247) p Value
Clinical characteristics
AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
CI = conﬁdence interval
HR = hazard ratio
LVEF = left ventricular
ejection fraction
MR = mitral regurgitation
TAVR = transcatheter aortic
valve replacement
VARC-2 = Valve Academic
Research Consortium 2R esidual aortic regurgitation (AR) is consideredto be one of the most important limitationsof transcatheter aortic valve replacement
(TAVR) with an incidence of mild or more than mild
paravalvular leaks of>50% inmost series, whichmark-
edly exceeds that observed after standard surgical
aortic valve replacement (1–3). Several studies have
shown that the presence of moderate to severe resid-
ual AR after TAVR is one of the strongest predictors
of acute mortality and at mid-term follow-up (1–14).
However, efforts to determine the clinical impact of
mild residual AR have yielded inconsistent results
(4,6,11,13–17), and whether mild AR after TAVR is
associated with poorer outcomes remains controver-
sial. Further clariﬁcation of this issue is of high clin-
ical relevance, especially considering both the
high incidence of mild AR after TAVR and the
potentially deleterious effects and costs associated
with additional measures for the treatment of
paravalvular leaks in such cases (e.g., balloon
post-dilation, implantation of a second valve, para-
valvular leak closure) (18–20).SEE PAGE 1033
Age, yrs 81  7 80  7 81  7* 80  8 0.002
Male 848 (48.9) 306 (42.1) 402 (52.8)* 140 (56.7)† <0.001
Body mass index, kg/m2 27  5 27  5 27  5* 26  5† <0.001
Hypertension 1,417 (81.7) 634 (87.3) 595 (78.2)* 188 (76.1)† <0.001
Diabetes 553 (31.9) 252 (34.7) 238 (31.3) 63 (25.6)† 0.024
NYHA functional class $3 1,403 (80.9) 585 (80.5) 620 (81.5) 198 (80.2) 0.833
Chronic atrial ﬁbrillation 403 (23.2) 140 (19.3) 208 (27.3)* 55 (22.3) 0.001
CABG 413 (23.8) 181 (24.9) 182 (23.9) 50 (20.2) 0.337
COPD 548 (31.6) 243 (33.4) 220 (29.2) 83 (33.6) 0.165
eGFR <60 ml/min 955 (55.0) 401 (55.2) 410 (53.9) 144 (58.3) 0.561
STS-PROM score, % 7.7  5.2 7.3  5.1 8.1  5.3* 7.6  5.0 0.003
Logistic EuroSCORE, % 20.8  13.9 20.3  13.7 21.5  14.1 20.5  13.9 0.119
Echocardiographic ﬁndings
LVEF <40% 327 (18.8) 119 (16.4) 146 (19.2) 62 (25.1)† 0.011
Aortic mean gradient,
mm Hg
46  17 45  16 47  16* 49  18† <0.001
Aortic valvular area, cm2 0.65  0.20 0.67  0.21 0.63  0.18* 0.64  0.18 0.018
Systolic pulmonary artery
pressure >55 mm Hg
268 (15.4) 98 (13.5) 125 (16.4) 45 (18.1) 0.116
Procedural ﬁndings
Approach <0.001
Transfemoral/subclavian 1,282 (73.9) 463 (63.7) 607 (79.8)* 212 (85.8)†‡
Transapical/transaortic 453 (26.1) 264 (36.3) 154 (20.2) 35 (14.2)
Prosthesis type <0.001
Self-expanding valve 753 (43.4) 281 (38.7) 325 (42.7) 147 (59.5)†‡
Balloon-expandable
valve
982 (56.6) 446 (61.3) 436 (57.3) 100 (40.5)
Prosthesis size <0.001
20–23 452 (26.1) 225 (30.9) 182 (23.9) 45 (18.2)
26 870 (50.1) 352 (48.4) 402 (52.8) 116 (47.0)†‡
29–31 413 (23.8) 150 (20.6) 177 (23.3)* 86 (34.8)†‡
Values are mean  SD or n (%). *p < 0.05 versus none/trace. †p < 0.05 versus none/trivial. ‡p < 0.05
versus mild.
AR ¼ aortic regurgitation; CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary dis-
ease; eGFR ¼ estimated glomerular ﬁltration ratio; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York
Heart Association; STS-PROM ¼ Society of Thoracic Surgeons predicted risk of mortality; TAVR ¼ transcatheter
aortic valve replacement.The early negative effect of residual AR on TAVR
candidates contrasts with the clinical evidence on the
impact of moderate or even severe AR in the overall
population, which commonly progress slowly, with a
long latency period before the appearance of symp-
toms or complications (21,22). It was recently sug-
gested that the acuteness of residual AR after TAVR
might have an impact on late mortality. In particular,
the worsening of $2 degrees in AR after TAVR was
found to be associated with increased mortality (4).
However, the degree of AR in this group of patients was
not detailed, no adjustment for confounding factors
was performed, and whether the impact of the acute-
ness of presentation of AR was independent of the
occurrence of moderate to severe AR was not deter-
mined. Moreover, few data exist on the impact of re-
sidual AR on cardiovascular outcomes, including
cardiac (rather than global) mortality and echocardio-
graphic parameters (6,17,23). The objectives of this
study, therefore, were the following: 1) to evaluate the
impact of the severity and acuteness of AR after TAVR
on clinical outcomes (global and cardiovascular) and 2)
to assess the impact of residual AR on left ventricular
ejection fraction (LVEF) and mitral regurgitation
(MR) changes as evaluated by echocardiography.
METHODS
STUDY POPULATION. A total of 1,783 consecutive
patients undergoing TAVR with balloon-expandablevalves (982 patients) and self-expanding
valves (753 patients) at 8 centers were eval-
uated. Forty-eight patients were excluded
because of the following reasons: unsuccess-
ful procedure without valve implantation in
30 patients, death during the ﬁrst 24 h after
TAVR before an echocardiogram was per-
formed in 17 patients, and concomitant
transcatheter mitral valve-in-valve implan-
tation in 1 patient. Therefore, the ﬁnal study
population consisted of 1,735 patients. Details
about the number of patients, and type of
valves in each center are provided in Online
Figure 1. Eligibility for TAVR, valve type, and access
TABLE 2 30-Day Clinical Outcomes According to the Severity of AR After TAVR
30-Day Outcomes
All
(n ¼ 1,735)
None to
Trace AR
(n ¼ 727)
Mild AR
(n ¼ 761)
Moderate to
Severe AR
(n ¼ 247) p Value
Permanent pacemaker
implantation
256 (14.8) 96 (13.2) 114 (15.0) 46 (18.6) 0.120
Myocardial infarction 17 (1.0) 7 (1.0) 9 (1.2) 1 (0.4) 0.539
Major/life-threatening bleeding 261 (15.0) 94 (12.9) 123 (16.2) 44 (17.8) 0.091
Major vascular complications 130 (7.5) 61 (8.4) 55 (7.3) 14 (5.7) 0.361
Acute kidney disease 322 (18.6) 122 (16.8) 145 (19.5) 55 (22.3) 0.087
Stroke 59 (3.4) 22 (3.0) 26 (3.4) 11 (4.5) 0.539
Death 95 (5.5) 31 (4.3) 35 (4.6) 29 (11.7)*† <0.001
Values are n (%). *Versus none/trace: odds ratio: 2.99, 95% conﬁdence interval: 1.76 to 5.07; p < 0.001. †Versus
mild: odds ratio: 2.76, 95% conﬁdence interval: 1.65 to 4.62; p < 0.001.
Abbreviations as in Table 1.
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1024route were determined at each center by a local heart
team composed of interventional cardiologists and
cardiac surgeons. Clinical, procedural, and echocar-
diographic data were prospectively gathered into a
TAVR database at each participating center. Out-
comes were deﬁned according to the Valve Academic
Research Consortium 2 (VARC-2) criteria (24).
Clinical follow-up was carried out in clinical visits
and/or through phone contact at 1 month, 6 to 12
months after TAVR, and yearly thereafter in all
participating centers. No patient was lost duringTABLE 3 Impact of the Severity of AR After TAVR on Cumulative Mo
None to
Trace AR
(n ¼ 727)
Mild AR
(n ¼ 761)
Overall mortality
No. of patients 153 (21.0) 212 (27.9)
Moderate to severe and mild vs.
none to trace AR
Univariate HR 1.00 (ref.) 1.11 (0.90–1.36)
Multivariate HR* 1.00 (ref.) 1.07 (0.84–1.37)
Moderate to severe vs. mild AR
Univariate HR 1.00 (ref.)
Multivariate HR* 1.00 (ref.)
Cardiovascular mortality
No. of patients 99 (13.6) 138 (18.1)
Moderate-severe and mild vs.
none-trace AR
Univariate HR 1.00 (ref.) 1.13 (0.87–1.46)
Multivariate HR* 1.00 (ref.) 1.11 (0.82–1.49)
Moderate-severe vs. mild AR
Univariate HR 1.00 (ref.)
Multivariate HR* 1.00 (ref.)
Values are n (%) or hazard ratio (95% conﬁdence interval). *Adjusted for differences i
body mass index, hypertension, diabetes, chronic atrial ﬁbrillation, STS-PROM, left v
transapical/transaortic approach, the use of balloon-expandable valves, prosthesis size,
ref. ¼ reference; other abbreviations as in Table 1.follow-up. Outcomes were deﬁned according to the
VARC-2 criteria.
ECHOCARDIOGRAPHIC ASSESSMENT. Transthoracic echo-
cardiography examinations were systematically
performed at baseline, after the procedure, and at
hospital discharge. Echocardiographic data at 6-
month to 12-month follow-up were available for
1,076 patients (71% of patients alive). Only trans-
thoracic echocardiography examinations were con-
sidered for the deﬁnition of AR. Echocardiograms
were analyzed by expert echocardiographers at each
center. The presence and degree of AR were evalu-
ated according to the VARC-2 criteria, and patients
were classiﬁed into 3 groups according to the severity
of residual AR: none to trace, mild, and moderate to
severe. In a further analysis, moderate to severe AR
was also subclassiﬁed as acute if there was $1 degree
of increase in AR compared with baseline and as
chronic when no changes or decrease in AR occurred
compared with baseline assessment. The LVEF was
evaluated in all patients using the Simpson biplane
methods. The presence of MR was also assessed in
all cases, and the severity was classiﬁed as none to
trace, mild, moderate, and severe according to
the recommendations of the American Society of
Echocardiography (25).rtality
Moderate to
Severe AR
(n ¼ 247)
p Value
Mild vs.
None
to Trace
Moderate to
Severe vs.
None to Trace
Moderate to
Severe vs.
Mild
89 (36.0)
1.60 (1.24–2.08) 0.350 <0.001
1.81 (1.32–2.48) 0.567 <0.001
1.45 (1.13–1.86) 0.003
1.68 (1.27–2.24) <0.001
61 (24.7)
1.72 (1.25–2.37) 0.371 0.001
1.68 (1.13–2.48) 0.514 0.010
1.53 (1.13–2.07) 0.006
1.52 (1.06–2.18) 0.024
n baseline characteristics, procedural ﬁndings, and 30 day-outcome: age, male sex,
entricular ejection fraction <40%, transvalvular aortic gradient, aortic valve area,
30-day life-threatening bleeding, and 30-day acute kidney injury.
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1025STATISTICAL ANALYSIS. Categorical variables are
presented as frequencies and continuous variables as
mean  SD. Transvalvular mean gradient, body mass
index, aortic valve area, STS-PROM (Society of
Thoracic Surgeons predicted risk of mortality), and
logistic EuroSCORE were skewed to the right and thus
were analyzed using a logarithmic transformation.
Comparisons of continuous variables were performed
using analysis of variance. The Fisher exact test was
used to compare qualitative variables. The Tukey test
for multiple comparisons was used if statistical sig-
niﬁcance was achieved. Logistic regression was used
to determine the independent predictors of 30-day
mortality. Cox regression models were used to
analyze the impact of AR on late mortality. Log-
transformed variables were entered into the models
after logarithmic transformation. Variables (baseline,
procedural, or post-procedural) with a p value < 0.10
on univariate analyses were included in multivariate
analyses. The proportional hazards assumption was
evaluated for all Cox models. Cumulative survival
rates were calculated by the Kaplan-Meier method
and compared with the log-rank test. A repeated-
measures model with interactions was used to
assess the changes in LVEF, MR, AR, mean trans-
valvular gradient, and aortic valve area over time
between groups. Further comparisons were per-
formed using the Bonferroni adjustment for multiple
testing. A 2-sided p value <0.05 was considered
signiﬁcant. All statistical analyses were conducted
using the statistical package SAS, version 9.2 (SAS
Institute Inc., Cary, North Carolina).FIGURE 1 Survival Curves According to the Degree of AR After TAVR
Kaplan-Meier curves at 3-year follow-up showing the percentage of patients free of death
(A) and cardiovascular death (B) according to the degree of aortic regurgitation (AR) after
transcatheter aortic valve replacement (TAVR).RESULTS
The main baseline and procedural characteristics of
the study population are shown in Table 1. A total of
1,008 patients (58.1%) had more than none to trace
AR after TAVR and residual AR was classiﬁed as mild
in 761 patients (43.9%) and moderate to severe in 247
patients (14.2%).
IMPACT OF THE SEVERITY OF AR ON MORTALITY.
Thirty-day outcomes of the study population ac-
cording to the severity of AR after TAVR are shown
in Table 2. No differences were observed in the rate
of periprocedural complications other than death
between groups (p > 0.05 for all). The presence of
moderate to severe AR was associated with increased
30-day mortality compared with none to trace
and mild AR groups (odds ratio [OR]: 2.99; 95%
conﬁdence interval [CI]: 1.76 to 5.07; p < 0.001 and
OR: 2.76, 95% CI: 1.65 to 4.62; p < 0.001, res-
pectively), and these differences persisted afteradjusting for baseline and procedural differences
(adjusted OR: 2.69; 95% CI: 1.34 to 5.38; p ¼ 0.005 and
adjusted OR: 2.41, 95% CI: 1.27 to 4.57; p ¼ 0.007 for
comparisons with none to trace and mild AR groups,
respectively). No increased risk of 30-day mortality
was observed in patients with mild AR compared
with none to trace AR (OR: 0.91, 95% CI: 0.73 to 1.12;
p ¼ 0.350).
At a mean follow-up of 21  17 months, 454 (26.2%)
patients had died: 153 (21.0%) patients in the none to
TABLE 4 Baseline Characteristics and Procedural Findings According to the
Occurrence of None to Mild, Acute or Chronic Moderate to Severe AR
None to
Trace to
Mild AR
(n ¼ 1,488)
Chronic
Moderate to
Severe AR
(n ¼ 86)
Acute
Moderate to
Severe AR
(n ¼ 161) p Value
Clinical characteristics
Age, yrs 81  7 80  9 80  8 0.677
Male 708 (47.6) 49 (57.0) 91 (56.5)† 0.030
Body mass index, kg/m2 27  5 25  5* 26  5 0.002
Hypertension 1,231 (82.7) 64 (74.4)* 122 (75.8)† 0.018
Diabetes 490 (32.9) 13 (15.1)* 50 (31.1)‡ 0.001
NYHA functional class $3 1,205 (81.0) 75 (87.2) 123 (76.4) 0.122
Chronic atrial ﬁbrillation 348 (23.4) 21 (24.4) 34 (21.1) 0.788
CABG 363 (24.4) 14 (16.3) 36 (22.4) 0.211
COPD 465 (31.3) 30 (34.9) 53 (32.9) 0.704
eGFR <60 ml/min 811 (54.5) 54 (62.8) 90 (55.9) 0.324
STS-PROM score, % 7.7  5.2 8.3  5.4 7.2  4.8 0.110
Logistic EuroSCORE, % 20.9  13.9 22.7  13.7 19.2  13.9 0.065
Echocardiographic
characteristics
LVEF <40% 265 (17.8) 18 (20.9) 44 (27.3)† 0.014
Aortic mean gradient,
mm Hg
46  16 50  18 48  17 0.043
Aortic valvular area, cm2 0.65  0.20 0.64  0.21 0.64  0.16 0.923
Systolic pulmonary artery
pressure >55 mm Hg
223 (15.0) 20 (23.3) 25 (15.5) 0.206
Procedural ﬁndings
Approach <0.001
Transfemoral/subclavian 1,070 (71.9) 80 (93.0)* 132 (82.0)†‡
Transapical/transaortic 418 (28.1) 6 (7.0) 29 (18.0)
Prosthesis type <0.001
Self-expanding valve 606 (40.7) 64 (74.4)* 83 (51.6)†‡
Balloon-expandable valve 882 (59.3) 22 (25.6) 78 (48.4)
Prosthesis size <0.001
20–23 407 (27.4) 10 (11.6) 35 (21.7)
25–26 754 (50.7) 38 (44.2)* 78 (48.4)
29–31 327 (22.0) 38 (44.2)* 48 (29.8)†‡
Values are mean  SD or n (%). *p < 0.05 versus none/trace. †p < 0.05 versus none/trivial.
‡p < 0.05 versus mild.
Abbreviations as in Table 1
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1026trace AR group, 212 patients (27.9%) in the mild AR
group, and 89 patients (36.0%) in the moderate to
severe AR group. The presence of moderate to severe
AR was associated with increased overall mortality
compared with patients with none to trace AR (hazard
ratio [HR]: 1.60, 95% CI: 1.24 to 2.08; p < 0.001) and
mild AR (HR: 1.45, 95% CI: 1.13 to 1.86; p < 0.001), and
these differences persisted after adjusting for base-
line and procedural differences between groups
(adjusted HR: 1.81; 95% CI: 1.32 to 2.48; p < 0.001 and
adjusted HR: 1.68, 95% CI: 1.27 to 2.24; p < 0.001 for
comparisons with none to trace and mild AR groups,
respectively). Also, moderate to severe AR was inde-
pendently associated with an increased risk of car-
diovascular mortality compared with none to trace
and mild AR groups (adjusted HR: 1.68, 95% CI: 1.13 to2.48; p ¼ 0.010 and adjusted HR: 1.52, 95% CI: 1.06 to
2.18; p ¼ 0.024, respectively). No increased overall or
cardiovascular mortality was observed in patients
with mild AR in both univariate and multivariate
analyses (p > 0.30 for all comparisons) (Table 3). The
Kaplan-Meier curves for overall and cardiovascular
mortality at 3-year follow-up according to the degree
of AR are shown in Figure 1.
IMPACT OF ACUTE (VS. CHRONIC) AR. To further
evaluate the impact of the acuteness of presentation
of AR in patients with moderate to severe AR after
TAVR, patients were reclassiﬁed into 3 groups: none/
trace/mild AR (n ¼ 1,448 [83%]), chronic moderate
to severe AR (n ¼ 86 [5.0%]), and acute moderate
to severe AR (n ¼ 161 [9.3%]). Baseline clinical and
echocardiographic characteristics and procedural
ﬁndings according to these groups are shown in
Table 4.
The rates of periprocedural complications other
than death were similar between groups (p > 0.10 for
all) (Table 5). Patients with acute moderate to severe
AR showed an increased risk of 30-day mortality
compared with the none/trace/mild AR group (OR:
3.59, 95% CI: 2.17 to 5.95; p < 0.001), and a trend to-
ward an increased mortality when comparing to
chronic moderate to severe AR (OR: 2.22, 95% CI: 0.87
to 5.69; p ¼ 0.096). On multivariate analysis, acute
moderate to severe AR strongly predicted 30-day
mortality compared with none/trace/mild (adjusted
OR: 4.81, 95% CI: 2.07 to 11.18; p < 0.001). No signif-
icant differences were observed compared with
chronic moderate to severe AR group (p ¼ 0.081).
There were no differences in 30-day mortality be-
tween chronic moderate to severe and none/trace/
mild AR groups (OR: 1.62, 95% CI: 0.68 to 3.84;
p ¼ 0.227).
At last follow-up, 365 patients (24.5%) with none to
mild AR, 23 patients (26.7) with chronic moderate to
severe AR, and 66 patients (41%) with acute moderate
to severe AR had died. The occurrence of acute
moderate to severe AR was an independent predictor
of overall mortality compared with none/trace/mild
AR (adjusted HR: 2.37; 95% CI: 1.53 to 3.66; p < 0.001)
and chronic moderate to severe AR (adjusted HR:
2.24, 95% CI: 1.17 to 4.30; p ¼ 0.015). Also, patients
with acute moderate to severe AR group exhibited an
increased cardiovascular mortality compared with
none/trace/mild AR (adjusted HR: 2.52, 95% CI: 1.48
to 4.32; p < 0.001) and chronic moderate to severe AR
(adjusted HR: 2.32, 95% CI: 1.03 to 5.20; p ¼ 0.041)
(Table 6). Differences between chronic and acute
moderate to severe AR groups persisted after further
adjustment including 30-day vascular complication,
TABLE 5 30-Day Outcomes According to None to Mild, Chronic Moderate to Severe, and
Acute Moderate to Severe AR Groups
None to Trace
to Mild AR
(n ¼ 1,488)
Chronic
Moderate to
Severe AR
(n ¼ 86)
Acute
Moderate
to Severe AR
(n ¼ 161) p Value
30-day outcomes
Permanent pacemaker implantation 210 (14.1) 18 (20.9) 28 (17.4) 0.134
Myocardial infarction 16 (1.1) 0 1 (0.6) 0.999
Major/life-threatening bleeding 217 (14.6) 14 (16.3) 30 (18.6) 0.354
Major vascular complications 116 (7.8) 3 (3.5) 11 (6.8) 0.349
Acute kidney disease 267 (17.9) 17 (19.8) 38 (23.6) 0.199
Stroke 48 (3.2) 2 (2.3) 9 (5.6) 0.279
Death 66 (4.4) 6 (7.0) 23 (14.3)*† <0.001
Values are n (%). *Versus none/trace/mild: odds ratio: 3.59, 95% conﬁdence interval: 2.17 to 5.95; p < 0.001.
†Versus chronic moderate to severe AR: odds ratio: 2.22, 95% conﬁdence interval: 0.87 to 5.69; p ¼ 0.096.
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1027stroke, and acute kidney injury on multivariate
analysis: adjusted HR: 2.15; 95% CI: 1.11 to 4.16; p ¼
0.023 for overall mortality and adjusted HR: 2.27,
95% CI: 1.01 to 5.11; p ¼ 0.048 for cardiovascular
mortality.
Survival curves at 3-year follow-up showing sur-
vival free of overall mortality and cardiovascular
mortality according to the occurrence of none/trace/
mild AR, chronic, and acute moderate to severe AR
after TAVR are shown in Figure 2.
ECHOCARDIOGRAPHIC FINDINGS. Changes in aortic
valve area and mean gradient according to the
occurrence of none to trace, mild, and moderate to
severe AR (chronic and acute) are shown in Figure 3.
Small variations in aortic valve area at discharge
and follow-up were observed between groups (p ¼
0.020 and 0.028, respectively), with no differences
in transvalvular mean gradient (p > 0.50 for all).
Changes in LVEF over time were similar between
groups (p ¼ 0.129), and no differences were observed
in LVEF at discharge and at follow-up between groups
(p > 0.2 for all) (Figure 4). Patients with acute mod-
erate to severe AR showed a poorer evolution of
MR over time compared with both patients with
none/trace/mild (p ¼ 0.042) and chronic moderate to
severe AR (p ¼ 0.008), whereas no differences wereTABLE 6 Impact of the Occurrence of None to Mild, Acute or Chronic
None to
Trace to
Mild AR
(n ¼ 727)
Chronic
Moderate to
Severe AR
(n ¼ 86)
Overall mortality
No. of patients 365 (24.5) 23 (26.7)
Acute and chronic moderate to severe
vs. none to mild AR
Univariate HR 1.00 (ref.) 0.94 (0.61–1.43
Multivariate HR* 1.00 (ref.) 1.06 (0.60–1.86
Acute vs. chronic moderate to
severe AR
Univariate HR 1.00 (ref.)
Multivariate HR* 1.00 (ref.)
Cardiovascular mortality
No. of patients 237 (15.9) 16 (18.6)
Acute and chronic moderate to severe
vs. none-mild AR
Univariate HR 1.00 (ref.) 1.03 (0.62–1.71)
Multivariate HR* 1.00 (ref.) 1.09 (0.54–2.21
Acute vs. chronic moderate to
severe AR
Univariate HR 1.00 (ref.)
Multivariate HR* 1.00 (ref.)
Values are n (%) or hazard ratio (95% conﬁdence interval). *Adjusted for differences in
pertension, diabetes, logistic EuroSCORE, left ventricular ejection fraction <40%, transv
prosthesis size.
Abbreviations as in Tables 1 and 3.encountered in the evolution of MR between chronic
moderate to severe and none/trace/mild AR groups
(p ¼ 0.170) (Figure 5). Although patients with none/
trace/mild AR and chronic moderate to severe AR
showed an improvement in MR severity over time
(p < 0.001 for both), no improvement in the presence
or severity of MR was observed in patients with acute
moderate to severe AR (p ¼ 0.951) (Figure 5). Differ-
ences in MR changes between groups persisted afterModerate to Severe AR After TAVR on Cumulative Mortality
Acute
Moderate to
Severe AR
(n ¼ 161)
p Value
Chronic Moderate
to Severe vs.
None/Trace/Mild
Acute Moderate
to Severe vs.
None/Trace/Mild
Acute vs.
Chronic Moderate
to Severe
66 (41.0)
) 1.93 (1.49–2.53) 0.755 <0.001
) 2.37 (1.53–3.66) 0.848 <0.001
2.07 (1.29–3.33) 0.003
2.24 (1.17–4.30) 0.015
45 (28.0)
2.02 (1.46–2.77) 0.917 <0.001
) 2.52 (1.48–4.32) 0.815 0.001
1.96 (1.11–3.47) 0.021
2.32 (1.03–5.20) 0.041
baseline characteristics, procedural ﬁndings, and 30 day-outcome: male sex, body mass index, hy-
alvular aortic gradient, transapical/transaortic approach, the use of balloon-expandable valves, and
FIGURE 2 Survival Curves According to the Degree and Acuteness of Presentation of
Post-Procedural AR
Kaplan-Meier curves at 3-year follow-up showing survival free of overall death (A) and
cardiovascular death (B) according to the occurrence of post-procedural none/trace/mild,
chronic, and acute moderate to severe aortic regurgitation (AR).
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1028adjusting for differences in baseline LVEF and mean
gradient (p ¼ 0.034).
No changes were observed in the severity of AR
from discharge to 6-month to 12-month follow-up
(improvement in AR was observed in 16% of pa-
tients, and worsening in 18%, p¼0.999) (Figure 6)
and the evolution of AR was similar between patients
with balloon-expandable and self-expanding valves(p ¼ 0.387). The degree of AR was greater in the
self-expanding valve group compared with the
balloon-expandable valve group at all points of
time (p # 0.002 for all) (Figure 6).
DISCUSSION
As many asw80% of patients undergoing TAVR show
some degree of paravalvular leak, classiﬁed as mild in
most of cases (2,3,12) and moderate to severe inw12%
of patients (14), similar to the proportion observed in
this study. Although few data exist on the impact of
mild AR after TAVR (4,13,14,17), some studies have
suggested an increased risk of mortality associated
with mild paravalvular leaks (4,13,14). Nonetheless,
this ﬁnding was based on the results of unadjusted
analyses, and it was not conﬁrmed after adjustments
for confounding variables (4,13,14). The present study
showed that the survival in patients mild AR was
similar to that observed in patients with none to trace
AR, even despite a higher STS-PROM score in the mild
AR group. This ﬁnding is consistent with most studies
on surgical aortic valve replacement including the
PARTNER I (Placement of Aortic Transcatheter Valve)
trial (1,26–28). Also, consistent with these results,
Yared et al. (17) did not ﬁnd increased mortality in
patients with mild AR after TAVR, and a substudy of
the Canadian TAVR experience showed that the
presence of mild AR was not associated with any
negative impact on left ventricular function parame-
ters up to 3-year follow-up (29).
Strong evidence exists on the negative impact of
residual moderate to severe AR on survival after
TAVR (1,5–11), and, in fact, it is deﬁned as device
failure according to the VARC-2 (24). Likewise, the
presence of moderate to severe AR after TAVR was an
independent predictor of overall and cardiovascular
mortality compared with both the none to trace and
mild AR groups in this study. Importantly, the negative
impact of moderate to severe AR was observed peri-
procedurally with a 3-fold increase in the risk of
30-day mortality and persisted over time with a 1.5-
fold increased risk of overall and cardiovascular mor-
tality at w2-year follow-up, conﬁrming the results of
previous smaller studies evaluating the risk of cardio-
vascular mortality associated with residual AR (6,23).
Hayashida et al. (4) reported that a worsening of $2
degrees in AR after TAVR was associated with a
poorer survival at 1-year follow-up. However, the rate
of moderate to severe AR in this group was not re-
ported, the model was not adjusted for potential
confounding factors, and no conclusion could be
drawn as to whether the impact of AR worsening was
independent of the presence of moderate to severe
FIGURE 3 Changes in Valve Hemodynamics Over Time
Changes in transaortic mean gradients and aortic valve area according to the occurrence of
none to trace, mild, chronic, and acute moderate to severe aortic regurgitation over time.
FIGURE 4 Changes in Left Ventricular Ejection Fraction Over
Time According to Study Groups
Of note, only patients with evaluation of the left ventricular
ejection fraction at the 3 points of time were included (N ¼
1,069).
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1029AR. In an step further, we found that any worsening
of the severity of AR (even by 1 degree) relative to
baseline with a ﬁnal degree of moderate to severe AR
was a strong independent predictor of mortality in
these patients. Of note, no differences in survival at
2-year follow-up were observed between patients
with chronic moderate to severe AR (no signiﬁcant
changes in AR severity between baseline and after
TAVR) and those with none to mild AR after TAVR,
strongly suggesting that the acuteness of AR presen-
tation plays a major role in the deleterious effects of
moderate to severe AR after TAVR. Any degree of AR
has been reported in as many as w86% of patients
with aortic stenosis, being moderate or greater in as
many as 45% (30), and the presence of AR at baseline
showed a protective effect in patients undergoing
TAVR because of severe aortic stenosis in the
FRANCE2 registry (31). However, this was not
conﬁrmed in the PARTNER trial (1), perhaps due to
the fact that moderate to severe AR at baseline was an
exclusion criterion in that trial.
It is well-known that acute AR is associated with a
poor prognosis in the overall population (32–36), un-
like that observed for chronic AR. Differences in
clinical impact between these 2 entities may be
explained by the presence of compensatory mecha-
nisms in chronic AR, which are lacking in acute AR,
ﬁnally leading to a rapid increase in end-diastolic
pressure relative to regurgitant volume and a low
forward stroke volume. Sinning et al. (11) reported
that the ratio of the gradient between diastolic blood
pressure and left ventricular end-diastolic pressure to
systolic blood pressure (AR index) is a strong predic-
tor of increased mortality in TAVR candidates, even
after adjusting for the severity of residual AR, and
this has been conﬁrmed by other studies (23). We
speculate that an AR index <0.25 might refer to pa-
tients with acute moderate to severe AR rather than
to all patients with moderate to severe AR, and this
could explain its superior impact on AR severity
assessment. No assessment of the AR index was
available in our study, and the correlation between
AR acuteness and index will have to be evaluated
in future studies.
The rapid increase in end-diastolic pressures in
acute AR usually leads to a worsening in MR to lower
diastolic pressures. Accordingly, the degree of MR did
not improve in patients with acute moderate to se-
vere AR after TAVR and tended to worsen despite the
relief of the left ventricular obstruction, whereas MR
severity signiﬁcantly improved over time in all other
TAVR groups. Of note, patients with chronic AR
showed a reduction in MR over time, suggesting a
decrease in end-diastolic pressures despite thepersistence of moderate to severe AR. This interplay
between MR and residual AR in patients undergoing
TAVR has been previously suggested (4) and also has
been reported for surgical prosthetic heart valves
(37,38). Nonetheless, the clinical relevance of differ-
ences in MR changes over time remains to be
determined.
In accordance with previous studies (17,29), no
impact of residual AR was observed on LVEF changes
over periods of time as long as 6 to 12 months of
follow-up. Several factors might have contributed to
FIGURE 5 Changes in MR Over Time
Changes according to the occurrence of none to trace, mild, chronic, and acute moderate
to severe aortic regurgitation (AR). Of note, only patients with evaluation of mitral
regurgitation (MR) at the 3 points of time were included (N ¼ 1,020). FU ¼ follow-up;
TAVR ¼ transcatheter aortic valve replacement.
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1030this ﬁnding. Consistent with previous studies (1), pa-
tients with moderate to severe AR had a lower LVEF
and a higher mean transaortic gradient at baseline. It
has been shown that a lower LVEF before TAVR is one
of the strongest predictors of improvement in LVEF
over time (39) and, therefore, greater improvement in
LVEF after the relief of valve obstruction may
compensate for any potential negative impact of re-
sidual AR in these patients. Also, moderate to severe
AR was associated with an increased early mortality.
Hence, those patients with moderate to severe AR
alive during the follow-up period might be those
exhibiting a lower impact of AR on left ventricular
function. Finally, a longer follow-up might be needed
to detect impairment in LVEF associated with the
occurrence of moderate to severe AR.
CLINICAL IMPLICATIONS. The results of this study
have important clinical implications. First, the lack of
impact of mild AR on 2-year clinical outcomes sug-
gests that additional therapeutic measures other than
a systematic follow-up are not necessary in such pa-
tients. On the other hand, a careful evaluation of the
baseline echocardiographic images is strongly sug-
gested in those patients diagnosed with moderate
to severe AR after TAVR. Considering the majorperiprocedural and late negative clinical impact
associated with the occurrence of acute AR leading to
an AR of a moderate to severe degree, all efforts
should be made to decrease the regurgitant volume in
such patients early in the postoperative period. Such
measures include balloon post-dilation, implantation
of a second valve, percutaneous closure of the para-
valvular leak with vascular plugs, or even cardiac
surgery and removal of the transcatheter valve
(18–20). Also, the implantation or manipulation of a
pacemaker to increase the baseline heart rate and
consequently decrease the diastolic ﬁlling time might
be useful to improve initial tolerance to moderate to
severe AR and bridge patients from acute to chronic
moderate to severe AR (40). Although these measures
may be associated with potential risks and increased
costs, their application seems to be justiﬁed by the
dismal prognosis associated with acute moderate to
severe AR after TAVR. In those patients with moderate
to severe AR after TAVR but no increase in AR severity
compared with baseline, a closer follow-up is probably
a reasonable option, as it has been in most patients
diagnosed with chronic AR. Additional measures for
the treatment of paravalvular leaks in such patients
should be implemented during the follow-up period if
any signiﬁcant deterioration in clinical status and/or
ventricular function parameters occurs.
STUDY LIMITATIONS. This study had no event adju-
dication committee. However, although this limita-
tion may be important for the quoting of some
complications, it may be less relevant when consid-
ering the endpoint of death (yes/no). The study might
be underpowered to detect signiﬁcant differences in
30-day mortality between the chronic and acute
moderate to severe AR groups. The assessment of AR
was based on the results of transthoracic echocar-
diograms analyzed at each center; no Echo Core Lab
was available in this study. Although echocardio-
graphic examinations were available in all patients at
baseline and during the hospitalization period,
echocardiographic data were missing in as many as
29% of the patients alive at follow-up. Also, the
impact of AR on left ventricular function over time
might have been underestimated because of the lack
of echocardiograms in patients who died within the
ﬁrst 6 months after TAVR. In the analysis of the
impact of AR on changes in MR over time, data on the
etiology of MR were not available and possible con-
founders were not adjusted for.
CONCLUSIONS
Residual AR is a frequent complication of TAVR. The
clinical impact (increased acute and late overall and
FIGURE 6 Changes in AR Over Time
Changes in aortic regurgitation (AR) in the overall population (A), in the balloon-expandable valve (BEV) group (B), in the self-expanding valve (SEV) group (C), and
comparisons between both groups (D). Of note, only patients with evaluation of AR at the 3 points of time were included (N ¼ 1,064; 543 patients in the BEV group
and 521 patients in the SEV group).
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1031cardiovascular mortality) of this complication was
mainly limited to those patients with moderate to
severe AR of acute origin (signiﬁcant increase vs.
baseline), suggesting that early additional measures
for the treatment of paravalvular leaks leading to a
decrease in the severity of AR in such patients are
probably of major clinical importance. The ﬁnal risk/
beneﬁt ratio of such a strategy will have to be deter-
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